NSCLC

This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.

nsclc

Most common lung cancer subtype (~85%); adenocarcinoma (KRAS/EGFR/ALK drivers), squamous cell carcinoma, and large cell. EGFR TKIs (osimertinib) and ALK inhibitors (alectinib) are highly active; pembrolizumab + chemotherapy transforms KRAS/squamous disease.

Entry Metadata

Field	Value
ID	nsclc
Name	NSCLC
Status	draft
Last reviewed	2026-06-06
Atlas	01-human
Scale	07-system

Cross-Atlas Connections

connects-toKras connects-toEgfr connects-toBraf connects-toPd 1 connects-toLung connects-toAlk connects-toType Ii Pneumocyte connects-toMelanoma connects-toT Cytotoxic Cell connects-toSclc

Sources

Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125. · PubMed 29151359
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833. · PubMed 27718347
Riely GJ, Ou SHI, Rybkin I, et al. KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring KRASG12C mutation. J Thorac Oncol. 2022;17(10):1248-1258. · PubMed 35817313